Platelet-type von Willebrand disease
MONDO:0008332A bleeding disorder characterized by mild to moderate mucocutaneous bleeding, which becomes more pronounced during pregnancy or following ingestion of drugs that have anti-platelet activity. PT-VWD is due to hyperresponsive platelets, resulting in thrombocytopenia.
Also known as: BDPLT3, PT-VWD, platelet type-von Willebrand disease, platelet-type von Willebrand disease, pseudo-von Willebrand disease, pseudo-von Willebrand disease type 2B, VWDP, Von Willebrand disease, Platelet-type
48 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New CAR-T therapy targets antibodies blocking Life-Saving transplants
Disease control Not yet recruitingThis early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…
Phase: PHASE1, PHASE2 • Sponsor: Chang Yingjun • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Could a feeding tube after transplant save the gut?
Disease control Not yet recruitingThis study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Ginger vs. heavy periods: a natural approach for women with bleeding disorders
Symptom relief Not yet recruitingThis study tests whether taking ginger powder for the first three days of each period can reduce heavy menstrual bleeding in women with coagulation disorders (bleeding problems). 74 women will be randomly assigned to receive either ginger or a placebo for six cycles. The goal is …
Phase: EARLY_PHASE1 • Sponsor: University of Valladolid • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC